including alcohol use disorder, across the lifespan. NIAAA is the world's largest funder of alcohol research.

Dated: June 16, 2021.

Vicki E. Buckley,

Associate Director of Administration, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health.

[FR Doc. 2021–13239 Filed 6–23–21; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; New Technologies for the In Vivo Delivery of Gene Therapeutics for an HIV Cure (R01 Clinical Trial Not Allowed).

Date: July 16, 2021.

Time: 10:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G22B, Rockville, MD 20892, (Virtual Meeting).

Contact Person: Kristina S. Wickham, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G22B, Rockville, MD 20852, 301–761–5390, *kristina.wickham@nih.gov*.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: June 17, 2021.

Tyeshia M. Roberson,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2021–13219 Filed 6–23–21; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Neurological Disorders and Stroke; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Neurological Disorders and Stroke Special Emphasis Panel; Clinical Trials in Neurology.

Date: July 12–13, 2021.

Time: 9:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Virtual Meeting).

Contact Person: Shanta Rajaram, Ph.D., Scientific Review Officer, Scientific Review Branch, Division of Extramural Activities, NINDS/NIH, NSC, 6001 Executive Blvd., Suite 3208, MSC 9529, Rockville, MD 20852, (301) 435–6033, *rajarams@mail.nih.gov*.

Name of Committee: National Institute of Neurological Disorders and Stroke Special Emphasis Panel; P01 Review.

Date: July 19–23, 2021.

Time: 9:00 a.m. to 2:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Virtual Meeting).

Contact Person: Li Jia, Ph.D., Scientific Review Officer, Scientific Review Branch, Division of Extramural Research, NINDS/NIH, 6001 Executive Boulevard, Room 3208D, Rockville, MD 20852, 301 451–2854, *li.jia@nih.gov*.

Name of Committee: National Institute of Neurological Disorders and Stroke Special Emphasis Panel; Initial Translation Efforts for Non-Addictive Analgesic Therapeutics Development.

Date: July 21–22, 2021.

Time: 9:30 a.m. to 3:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Virtual Meeting).

Contact Person: Diana M. Cummings, Ph.D., Scientific Review Officer, Scientific Review Branch, National Institute of Neurological Disorders and Stroke, NIH, NSC, 6001 Executive Blvd., Suite 3208, Rockville, MD 20852, *cummingsdi@ninds.nih.gov*.

(Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS)

Dated: June 15, 2021.

Tyeshia M. Roberson,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2021–13347 Filed 6–23–21; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Child Health and Human Development Initial Review Group Developmental Biology Study Section.

Date: June 25, 2021.

Time: 9:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, 6710B Rockledge Drive, 2121D, Bethesda, MD 20817, (Virtual Meeting).

Contact Person: Cathy J. Wedeen, Ph.D., Scientific Review Officer, Scientific Review Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, 6710B Rockledge Drive, Room 2121D, Bethesda, MD 20892–7510, (301) 435–6878, *cathy.wedeen@nih.gov*.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.864, Population Research; 93.865, Research for Mothers and Children; 93.929, Center for Medical Rehabilitation Research; 93.209, Contraception and Infertility Loan Repayment Program, National Institutes of Health, HHS)

Dated: June 14, 2021.

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2021–13354 Filed 6–23–21; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of an Exclusive Patent License: Development and Commercialization of Monospecific CD22 Chimeric Antigen Receptor (CAR) Therapies for the Treatment of B-Cell Malignancies

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this Notice to Syncopation Life Sciences Inc., (''Syncopation''), located in Palo Alto, California.

DATES: Only written comments and/or complete applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before July 9, 2021 will be considered.

ADDRESSES: Requests for copies of the patent applications, inquiries, and comments relating to the contemplated Exclusive Patent License should be directed to: Jim Knabb, Senior Technology Transfer Manager, at Telephone: (240)–276–7856; or at Email: *jim.knabb@nih.gov.*

SUPPLEMENTARY INFORMATION:

Intellectual Property

E–080–2012–0: Human Monoclonal Antibodies Specific for CD22

1. U.S. Provisional Patent Application 61/042,329, filed April 4, 2008 (E–080–2008–0–US–01);

2. International Patent Application PCT/US2009/039,080, Filed April 1, 2009 (E–080–2008/0–PCT–02);

3. U.S. Patent Application: 12/934,214, filed September 23, 2010 (E–080–2008–0–US–03);

4. U.S. Patent Application 13/959,061, filed August 5, 2015 (E–080–2008–0–US–04);

5. U.S. Patent Application 15/012,023, filed February 1, 2016 (E–080–2008–0–US–05);

6. U.S. Patent Application 15/424,238, filed February 3, 2017 (E–080–2008–0–US–06).

E–291–2012–0: M971 Chimeric Antigen Receptors

1. U.S. Provisional Patent Application 61/717,960, filed October 24, 2012 (E–291–2012–0–US–01);

2. International Patent Application PCT/US2013/060332, filed September 18, 2013 (E–291–2012–0–PCT–02);

3. Australia Application No: 2019235926, filed September 2, 2020 (E–291–2012–0–AU–03);

4. Brazil Patent Application BR112015009003–6, filed April 22, 2015 (E–291–2012–0–BR–04);

5. Canada Application No: 2889055, filed September 18, 2013 (E–291–2012–0–CA–05);

6. China Application No: 201380061387.5, filed May 25, 2015 (E–291–2012–0–CN–06);

7. European Patent Application No: 13773468.7, filed September 18, 2013 (E–291–2012–0–EP–07);

8. India Patent Application No: 2344/CHENP/2015, filed September 18, 2013 (E–291–2012–0–IN–08);

9. Japan Application No: 539602/2015, filed April 24, 2015 (E–291–2012–0–JP–09);

10. Russia Patent Application: 2015117237, filed May 7, 2015 (E–291–2012–0–RU–10);

11. U.S. Patent Application: 14/437,889, filed April 23, 2015 (E–291–2012–0–US–11);

12. Hong Kong Patent Application: 16101891.0, filed February 19, 2016 (E–291–2012–0–HK–12);

13. Russia Patent Application: 2018116582, filed May 4, 2018 (E–291–2012–0–RU–13);

14. Japan Patent Application: 2018–088908, filed May 2, 2018, (E–291–2012–0–JP–14);

15. Australia Patent Application: 2018204257, filed June 14, 2018 (E–291–2012–0–AU–16);

16. U.S. Patent Application: 16/107,271, filed August 21, 2018 (E–291–2012–0–US–17);

17. Germany Patent Application: 13773468.7, filed April 22, 2015 (E–291–2012–0–DE–18);

18. Spain Patent Application: 13773468.7, filed April 22, 2015 (E–291–2012–0–ES–19);

19. France Patent Application: 13773468.7, filed April 22, 2015 (E–291–2012–0–FR–20);

20. Great Britain Patent Application: 13773468.7, filed April 22, 2015 (E–291–2012–0–GB–21);

21. Italy Patent Application: 13773468.7, filed April 22, 2015 (E–291–2012–0–IT–22);

22. China Patent Application: 201910500128.7, filed June 11, 2019 (E–291–2012–0–CN–23);

23. U.S. Patent Application: 16/869,792, filed May 8, 2020 (E–291–2012–0–US–24).

The patent rights in these inventions have been assigned and/or exclusively licensed to the government of the United States of America.

The prospective exclusive license territory may be worldwide, and the fields of use may be limited to the following:

''Development, manufacture and commercialization of chimeric antigen receptor T cell (CAR–T) immunotherapies (both autologous and allogeneically derived) for the treatment of B cell malignancies that express CD22 wherein:

1. The T cells are engineered to be monospecific for CD22; and

2. The chimeric antigen receptor is specific for CD22 via the m971 scFv''.

This technology discloses CAR therapies that target CD22 by utilizing the anti-CD22 binder known as m971. CD22 is expressed on the surface of B cells in B cell malignancies and CD22-targeting CAR–T has shown early promise in clinical trials for ALL and NHL.

This Notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license will be royalty bearing, and the prospective exclusive license may be granted unless within fifteen (15) days from the date of this published Notice, the National Cancer Institute receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.

In response to this Notice, the public may file comments or objections. Comments and objections, other than those in the form of a license application, will not be treated confidentially, and may be made publicly available.

License applications submitted in response to this Notice will be presumed to contain business confidential information and any release of information from these license applications will be made only as required and upon a request under the